Skip to main content

Insmed Inc(INSM-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low141.43
Day High145.76
Open:141.46
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.

Top Stories: Insmed Inc

Select a category then submit the form to load news
Motley Fool
Investment Manager Bets Big on PTCT Stock, Adds 41,000 Shares, According to Recent SEC Filing
Motley Fool
Investment Firm Adds Nearly $4 Milllion Worth of DYN Shares, According to Recent SEC Filing
Motley Fool
Investment Advisor Bets Big on CMPX Stock, Adds 2.5 Million Shares, According to Latest SEC Filing
Tipranks
Insmed (INSM) Receives a Buy from Evercore ISI
Tipranks
Analysts Have Conflicting Sentiments on These Healthcare Companies: Sarepta Therapeutics (SRPT), Insmed (INSM) and Carlsmed, Inc. (CARL)
Tipranks
Analysts Are Bullish on Top Healthcare Stocks: Travere Therapeutics (TVTX), Insmed (INSM)
Tipranks
H.C. Wainwright Remains a Buy on Insmed (INSM)
Motley Fool
Investor Buys Up $81 Million in Praxis Stock as Shares Soar Over 300% in One Year
Motley Fool
This Fund Bet Nearly $40 Million on GRAIL Last Quarter. The Stock Just Plunged Over 50%
Tipranks
Analysts Offer Insights on Healthcare Companies: Insmed (INSM) and 10x Genomics (TXG)
Tipranks
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Hims & Hers Health (HIMS) and Insmed (INSM)
Tipranks
RBC Capital Reaffirms Their Buy Rating on Insmed (INSM)
Tipranks
Bank of America Securities Reaffirms Their Buy Rating on Insmed (INSM)
Tipranks
Analysts’ Top Healthcare Picks: Insmed (INSM), Irhythm Technologies (IRTC)
Tipranks
Insmed’s Brinsupri Launch Recasts Growth Outlook
Tipranks
Analysts Offer Insights on Healthcare Companies: Talkspace (TALK) and Insmed (INSM)
Tipranks
Insmed director McGirr to step down after 2026 meeting
Motley Fool
Insmed (INSM) Q4 2025 Earnings Call Transcript
Tipranks
Roth MKM Sticks to Their Buy Rating for Insmed (INSM)
Motley Fool
Biotech Exit: $26 Million Arcellx Sale Follows Tepid Stock Performance and Kelonia Competition
Motley Fool
Cogent Biosciences Stock Up 346% as Fund Builds $29 Million Stake After November Phase 3 Breakthrough
Motley Fool
Fund Discloses $35 Million Biotech Buy Amid Staggering 830% Terns Stock Surge
Motley Fool
Biotech Stock Up 266%: This New $55 Million Bet Signals Conviction in Praxis Amid Pipeline Progress
Motley Fool
Apogee Stock Jumps 87% in One Year as This Biotech Fund Lifts Stake to $93 Million
ValuEngine, Inc
02/09/2026 ValuEngine Weekly Market Summary & Commentary
Tipranks
Analysts Offer Insights on Healthcare Companies: Insmed (INSM), Oncolytics Biotech (ONCY) and Imunon (IMNN)
Tipranks
Insmed’s ENCORE Trial Reaches Key Milestone in MAC Lung Infection
Tipranks
Bank of America Securities Keeps Their Buy Rating on Insmed (INSM)
Tipranks
Morgan Stanley Sticks to Its Hold Rating for Insmed (INSM)
Tipranks
Analysts Offer Insights on Healthcare Companies: Insmed (INSM) and Roche Holding AG (OtherRHHVF)
Tipranks
Analysts Are Bullish on Top Healthcare Stocks: Insmed (INSM), Sanara MedTech (SMTI)
Tipranks
Insmed (INSM) Receives a Buy from Stifel Nicolaus

Profile

Insmed is a biopharmaceutical company engaged in the development and commercialization of ARIKAYCE, or liposomal amikacin for inhalation, for at least two identified orphan patient populations: patients with nontuberculous mycobacteria (NTM) lung infections and cystic fibrosis (CF) patients with Pseudomonas aeruginosa lung infections. Insmed is also focused on the development of INS1009, the company's inhaled treprostinil prodrug for the treatment of pulmonary arterial hypertension (PAH), a chronic, life-threatening disorder characterized by abnormally high blood pressure in the arteries between the heart and lungs.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.